Diabetes Research and Clinical Practice
Volume 90, Issue 2 , Pages 154-159 , November 2010

Cost-effectiveness of administering oral adsorbent AST-120 to patients with diabetes and advance-stage chronic kidney disease

  • Yasuaki Hayashino

      Affiliations

    • Department of Epidemiology and Healthcare Research, Kyoto University Graduate School of Medicine, Konoe-cho, Yoshida, Sakyo-ku, Kyoto 606-8501, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 75 753 9467; fax: +81 75 753 4644.
    • ,
  • Shunichi Fukuhara

      Affiliations

    • Department of Epidemiology and Healthcare Research, Kyoto University Graduate School of Medicine, Konoe-cho, Yoshida, Sakyo-ku, Kyoto 606-8501, Japan
    • ,
  • Tadao Akizawa

      Affiliations

    • Department of Nephrology, Showa University School of Medicine, Tokyo, Japan
    • ,
  • Yasushi Asano

      Affiliations

    • Department of Internal Medicine, Koga Red-Cross Hospital, Ibaraki, Japan
    • ,
  • Takafumi Wakita

      Affiliations

    • Institute for Health Outcomes and Process Evaluation Research, Kyoto, Japan
    • Department of Psychology, Faculty of Sociology, Kansai University, Osaka, Japan
    • ,
  • Yoshihiro Onishi

      Affiliations

    • Institute for Health Outcomes and Process Evaluation Research, Kyoto, Japan
    • ,
  • Kiyoshi Kurokawa

      Affiliations

    • National Graduate Institute for Policy Studies, Tokyo, Japan
    • ,
  • for the CAP-KD study group

Received 12 March 2010 ,Revised 12 July 2010 ,Accepted 15 July 2010.

References 

  1. Gaster B, Hirsch IB. The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med. 1998;158(2):134–140
  2. Parving HH. Clinical experience in the treatment of diabetic renal disease (type 1 and 2): summary and concluding remarks. Kidney Int. 1994;45(Suppl.):165–166
  3. Parving HH. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1994;330(13):937–938
  4. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869
  5. Bertoni AG, Krop JS, Anderson GF, Brancati FL. Diabetes-related morbidity and mortality in a national sample of U.S. elders. Diabetes Care. 2002;25(3):471–475
  6. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286(10):1195–1200
  7. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289(1):76–79
  8. Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the U.S.: 1990–1998. Diabetes Care. 2000;23(9):1278–1283
  9. Nakai S, Masakane I, Akiba T, et al. Overview of regular dialysis treatment in Japan as of 31 December 2006. Ther Apher Dial. 2008;12(6):428–456
  10. United States Renal Data System . Patient mortality and survival. Am J Kidney Dis. 1998;32(2 (Suppl. 1)):S69–S80
  11. Ritz E, Stefanski A. Diabetic nephropathy in type II diabetes. Am J Kidney Dis. 1996;27(2):167–194
  12. Aoyama I, Shimokata K, Niwa T. Combination therapy with benazepril and oral adsorbent ameliorates progressive renal fibrosis in uremic rats. Nephron. 2002;90(3):297–312
  13. Miyazaki T, Aoyama I, Ise M, Seo H, Niwa T. An oral sorbent reduces overload of indoxyl sulphate and gene expression of TGF-beta1 in uraemic rat kidneys. Nephrol Dial Transplant. 2000;15(11):1773–1781
  14. A study of AST-120 for evaluating prevention of progression in chronic kidney disease (EPPIC-1). ClinicalTrials.gov; 2008;
  15. Akizawa T, Asano Y, Morita S, et al. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis. 2009;54(3):459–467
  16. Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med. 1999;131(9):660–667
  17. Beck JR, Kassirer JP, Pauker SG. A convenient approximation of life expectancy (the “DEALE”). I. Validation of the method. Am J Med. 1982;73(6):883–888
  18. Beck JR, Pauker SG, Gottlieb JE, Klein K, Kassirer JP. A convenient approximation of life expectancy (the “DEALE”). II. Use in medical decision-making. Am J Med. 1982;73(6):889–897
  19. Kunz K, Weinstein M. Modelling in economic evaluation. In:  Drummond M,  McGuire M editor. Economic evaluation in health care: merging theory with practice. New York, NY: Oxford University Press; 2001;
  20. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis. 2006;48 (Suppl. 1):S2–S90
  21. Arias E. United States life tables, 2004. Natl Vital Stat Rep. 2007;56(9):1–39
  22. The Japanese Society for Dialysis Therapy . The crude 1-yr mortality rates among hemodialysis patients. 2008;Available at http://docs.jsdt.or.jp/overview/pdf2009/p021.pdf (accessed 14.06.10)
  23. Gold M, Siegel J, Russel L, Weinstein MC. Cost-effectiveness in health and medicine. Philadelphia: Saunders; 1996;
  24. The Diabetes Control and Complications Trial Research Group . Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA. 1996;276(17):1409–1415
  25. Lawrence WF, Grist TM, Brazy PC, Fryback DG. Magnetic resonance angiography in progressive renal failure: a technology assessment. Am J Kidney Dis. 1995;25(5):701–709
  26. Brown GC, Brown MM, Sharma S, Brown H, Gozum M, Denton P. Quality of life associated with diabetes mellitus in an adult population. J Diabetes Complications. 2000;14(1):18–24
  27. Takahashi T, Reed SD, Schulman KA. Cost-effectiveness of the oral adsorbent AST-120 versus placebo for chronic kidney disease. Nephrology (Carlton). 2008;13(5):419–427
  28. Japanese Ministry of Health Labour and Welfare . Standard prices for medicines in 2008. Tokyo: Shakai-hoken Kenkyujyo; 2006;
  29. Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S. Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med. 2005;143(2):89–99
  30. Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med. 2004;19(6):638–645
  31. Okada K, Shibahara H, Takahashi S. Effect of oral adsorbent on the progression of diabetic nephropathy. Nephron. 1997;76(4):489–490
  32. Aoyama I, Shimokata K, Niwa T. Oral adsorbent AST-120 ameliorates interstitial fibrosis and transforming growth factor-beta(1) expression in spontaneously diabetic (OLETF) rats. Am J Nephrol. 2000;20(3):232–241
  33. I. NKF-K/DOQI clinical practice guidelines for hemodialysis adequacy: update 2000. Am J Kidney Dis. 2001;37(1 (Suppl. 1)):S7–S64

PII: S0168-8227(10)00362-1

doi: 10.1016/j.diabres.2010.07.007

Diabetes Research and Clinical Practice
Volume 90, Issue 2 , Pages 154-159 , November 2010

Article Tools

* Image Usage & Resolution